Evidence map›Paper›PMID 37452070›Full record

ArticleCell death & disease2023

Efferocytosis by bone marrow mesenchymal stromal cells disrupts osteoblastic differentiation via mitochondrial remodeling.

Emily R Quarato, Noah A Salama, Allison J Li, Charles O Smith, Jane Zhang, Yuko Kawano, Matthew McArthur, Jane L Liesveld, Michael W Becker, Michael R Elliott and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Immune Aging as a Failure of Programmed Cell Death Coordination.International journal of molecular sciences · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Engineering Efferocytosis for Bone Regeneration.Macromolecular bioscience · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Efferocytosis and Bone Dynamics.Current osteoporosis reports · 2024
    Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Emily R QuaratoDepartment of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA. Emily_Quarato@urmc.rochester.edu.ORCID 0000-0002-1434-5670
Noah A SalamaJames P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Allison J LiDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Charles O SmithCenter for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA.
Jane ZhangJames P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Yuko KawanoJames P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Matthew McArthurCenter for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY, USA.
Jane L LiesveldJames P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Michael W BeckerJames P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Michael R ElliottUniversity of Virginia, Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, VA, USA.
Roman A EliseevJames P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-6783-7388
Laura M CalviJames P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. laura_calvi@urmc.rochester.edu.
University of Rochester Medical Center · USUniversity of Virginia · USYale University · US

Funding

Training in Environment ToxicologyT32ES007026 · NIEHS · UNIVERSITY OF ROCHESTER · PI Alison Elder, Marissa Sobolewski Terry · 1985 to 2026
$20.2M
Rochester Resource-Based Center for Bone, Muscle and Orthopaedic Research (ROCSTARR) (Overall Application)P30AR069655 · NIAMS · UNIVERSITY OF ROCHESTER · PI Edward M. Schwarz · 2016 to 2026
$7.8M
The University of Rochester Core Center for Musculoskeletal Biology and MedicineP30AR061307 · NIAMS · UNIVERSITY OF ROCHESTER · PI SCHWARZ, EDWARD M. · 2011 to 2015
$3.0M
Mechanisms of marrow microenvironmental aging and their impact of progression of clonal hematopoiesisR01AG079556 · NIA · UNIVERSITY OF ROCHESTER · PI Laura M Calvi, JANE L. LIESVELD · 2022 to 2026
$2.7M
Efferocytosis by Bone Marrow Stromal Cells and Bone AgingR01AG076786 · NIA · UNIVERSITY OF ROCHESTER · PI Laura M Calvi, Roman Eliseev · 2022 to 2026
$2.4M
Mitochondrial metabolism and bone formationR01AR072601 · NIAMS · UNIVERSITY OF ROCHESTER · PI ELISEEV, ROMAN · 2018 to 2022
$1.7M
NIAMS NIH HHS P30 AR061307NIAMS NIH HHS P30 AR069655NIAMS NIH HHS R01 AR072601NIA NIH HHS R01 AG076786NIA NIH HHS R01 AG079556NIEHS NIH HHS T32 ES007026
6 · The paper itself

Abstract

The efficient clearance of dead and dying cells, efferocytosis, is critical to maintain tissue homeostasis. In the bone marrow microenvironment (BMME), this role is primarily fulfilled by professional bone marrow macrophages, but recent work has shown that mesenchymal stromal cells (MSCs) act as a non-professional phagocyte within the BMME. However, little is known about the mechanism and impact of efferocytosis on MSCs and on their function. To investigate, we performed flow cytometric analysis of neutrophil uptake by ST2 cells, a murine bone marrow-derived stromal cell line, and in murine primary bone marrow-derived stromal cells. Transcriptional analysis showed that MSCs possess the necessary receptors and internal processing machinery to conduct efferocytosis, with Axl and Tyro3 serving as the main receptors, while MerTK was not expressed. Moreover, the expression of these receptors was modulated by efferocytic behavior, regardless of apoptotic target. MSCs derived from human bone marrow also demonstrated efferocytic behavior, showing that MSC efferocytosis is conserved. In all MSCs, efferocytosis impaired osteoblastic differentiation. Transcriptional analysis and functional assays identified downregulation in MSC mitochondrial function upon efferocytosis. Experimentally, efferocytosis induced mitochondrial fission in MSCs. Pharmacologic inhibition of mitochondrial fission in MSCs not only decreased efferocytic activity but also rescued osteoblastic differentiation, demonstrating that efferocytosis-mediated mitochondrial remodeling plays a critical role in regulating MSC differentiation. This work describes a novel function of MSCs as non-professional phagocytes within the BMME and demonstrates that efferocytosis by MSCs plays a key role in directing mitochondrial remodeling and MSC differentiation. Efferocytosis by MSCs may therefore be a novel mechanism of dysfunction and senescence. Since our data in human MSCs show that MSC efferocytosis is conserved, the consequences of MSC efferocytosis may impact the behavior of these cells in the human skeleton, including bone marrow remodeling and bone loss in the setting of aging, cancer and other diseases.

Indexed as

Bone MarrowMesenchymal Stem CellsAnimalsBone Marrow CellsCell DifferentiationHumansMiceMitochondriaPhagocytosis

Identifiers

PMID37452070
PMCPMC10349065
OpenAlexW4384339299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.